GOSS
Gossamer Bio
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
GOSS Profile
Gossamer Bio, Inc.
A clinical-stage biopharmaceutical company that developing therapeutics in the disease areas of immunology, inflammation and oncology
Biological Technology
10/26/2015
02/08/2019
NASDAQ Stock Exchange
144
12-31
Common stock
3013 Science Park Road, San Diego, California 92121
--
Gossamer Bio, Inc., was incorporated under Delaware law on October 26, 2015 under the name FSG, Bio, Inc., and changed its name to Gossamer Bio, Inc., Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, in 2017, Focus on the development and commercialization of ceratinib for the treatment of pulmonary hypertension or PAH. The company's goal is to become an industry leader and improve the lives of patients with pulmonary hypertension, or PH. To achieve this goal, the company brings together a group of experienced and skilled industry veterans, scientists, clinicians and key opinion leaders from leading biotechnology and pharmaceutical companies, as well as leading academic centers from around the world. The company intends to maintain a corporate culture of scientific rigor and inclusiveness, with employees striving to bring patients better treatment options.